The biotech company $BMEA has recently conducted a weight reduction study on obese monkeys, showing promising results. They have upcoming catalysts such as potential partnerships, diabetes data releases, and FDA trial acceptances. The company's stock is considered de-risked with multiple positive developments on the horizon. Additionally, their drugs have potential in oncology, with the possibility of generating significant revenue in the future. Investors are optimistic about the company's future prospects.

BMEA stock price is 1.875. BMEA 52 Week low is None. BMEA 52 Week high is None. BMEA 200 day moving average is 4.88. It is currently trading below 200 day moving average. BMEA 50 day moving average is 1.93 which is above(bearish) the current price. RSI (relative strength index) of BMEA is 46.244 which is below (bearish) 70. Chaikin money flow (20 day) of BMEA is 0.3 which is above (bullish) 0.